Illinois Municipal Retirement Fund Reduces Position in Kenvue Inc. (NYSE:KVUE)

Illinois Municipal Retirement Fund trimmed its holdings in Kenvue Inc. (NYSE:KVUE) by 29.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 365,434 shares of the company’s stock after selling 152,999 shares during the quarter. Illinois Municipal Retirement Fund’s holdings in Kenvue were worth $7,802,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of the business. Grove Bank & Trust increased its holdings in shares of Kenvue by 438.4% in the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock valued at $25,000 after purchasing an additional 947 shares during the last quarter. Geneos Wealth Management Inc. purchased a new stake in Kenvue in the 4th quarter valued at $29,000. Fortitude Family Office LLC increased its stake in shares of Kenvue by 106.6% in the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock worth $32,000 after acquiring an additional 777 shares during the last quarter. Ashton Thomas Securities LLC purchased a new position in shares of Kenvue during the 3rd quarter worth $35,000. Finally, Versant Capital Management Inc boosted its position in shares of Kenvue by 300.8% during the 4th quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock valued at $41,000 after acquiring an additional 1,441 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. UBS Group cut their price objective on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a research report on Friday, February 7th. Deutsche Bank Aktiengesellschaft lowered shares of Kenvue from a “buy” rating to a “hold” rating and reduced their price target for the company from $25.00 to $24.00 in a research report on Thursday, December 12th. Piper Sandler increased their price objective on Kenvue from $24.00 to $27.00 and gave the stock an “overweight” rating in a research report on Monday. Barclays reduced their target price on Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a research report on Friday, January 17th. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $24.00 price target on shares of Kenvue in a research note on Monday, February 3rd. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, Kenvue currently has an average rating of “Hold” and an average target price of $23.08.

Kenvue Stock Performance

Shares of Kenvue stock opened at $23.22 on Thursday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The stock has a market capitalization of $44.52 billion, a price-to-earnings ratio of 43.81, a price-to-earnings-growth ratio of 2.62 and a beta of 1.45. The business has a 50-day moving average of $21.36 and a 200 day moving average of $22.23. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.46.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. As a group, sell-side analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th were given a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.53%. The ex-dividend date was Wednesday, February 12th. Kenvue’s dividend payout ratio is currently 154.72%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.